CD96 Protein (CD96) (AA 22-503) (Fc Tag)

Catalog No. ABIN6253540

Product Details

Target: CD96

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 22-503

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This CD96 protein is labelled with Fc Tag.

Sequence: AA 22-503

Characteristics: This protein carries a mouse IgG2a Fc tag at the C-terminus. The protein has a calculated MW of 80.6 kDa. The protein migrates as 32 KDa, 34 KDa and 120 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Purity: >90 % as determined by reduced SDS-PAGE.

Endotoxin Level: Less than 0.1 EU per μg by the LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Tris with Glycine, Arginine and NaCl,  pH 7.5

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

Target Details

Target: CD96

Alternative Name: CD96 (CD96 Products)

Synonyms: 1700109I12Rik Protein, Tactile Protein, TACTILE Protein, CD96 antigen Protein, CD96 molecule Protein, Cd96 Protein, CD96 Protein

Background: The progression of pancreatic cancer (PC) is significantly associated with tumor immune escape, which may be associated with nature killer (NK) cell dysfunction. CD226, CD96, and TIGIT, which share the ligand CD155, play important roles in the regulation of NK cell function. The present study was conducted to investigate the roles of these molecules in NK cells from PC patients. TIGIT and CD96 together with the co-stimulatory receptor CD226 form a pathway that is analogous to the CD28/CTLA-4 pathway, in which shared ligands and differential receptor:ligand affinities fine-tune the immune response. Although the roles of TIGIT and CD96 as immune checkpoint receptors in T cell and natural killer cell biology are just beginning to be uncovered, accumulating data support the targeting of these receptors for improving anti-tumor immune responses. A clear understanding of the immune cell populations regulated by TIGIT and CD96 is key to the design of immunotherapies that target these receptors in combination with other existing immune checkpoint blockade therapies. The dysfunction of CD96 may trigger C syndrome: A syndrome characterized by trigonocephaly, severe mental retardation, hypotonia, variable cardiac defects, redundant skin, and dysmorphic facial features, including upslanted palpebral fissures, epicanthal folds, depressed nasal bridge, and low-set, posteriorly rotated ears.

Molecular Weight: 80.4 kDa

NCBI Accession: NP_005807